肿瘤药学2019，Vol.9Issue(2)：270-274,5.DOI:10.3969/j.issn.2095-1264.2019.02.19
阿瑞匹坦预防骨与软组织肿瘤患者接受高致吐化疗所致恶心、呕吐的研究
Aprepitant in the Prevention of Nausea and Vomiting Induced by Hyperemetic Chemotherapy in Patients with Bone and Soft Tissue Tumors
ZHANG Jiao 1LIU Huayun 2WANG Yuhua1
作者信息
- 1. Orthopedics & Soft Tissue Department, the Affiliated Cancer Hospital of Xi-angya School of Medicine, Central South University, Changsha, Hunan, 410013, China
- 2. Nursing Department, Hunan Cancer Hospital ,the Affiliated Cancer Hospital of Xi-angya School of Medicine, Central South University, Changsha, Hunan, 410013, China
- 折叠
摘要
Abstract
Objective To investigate the safety and efficacy of aprepitant in the prevention of nausea and vomiting induced by hyperemetic chemotherapy in patients with malignant bone and soft tissue tumors. Methods Between May 2016 and May 2018, 100 patients with malignant tumor in bone and soft tissue were enrolled in this retrospective study. According to the prophylactic antiemetic drugs before chemotherapy, patients were divided into two groups: aprepitant group (n=50) and control group (n=50). Observe the complete remission (CR) rate of nausea and vomiting in two groups within 120 hours. Results The CR rates of nausea within 24 hours were 84% (42/50) and 76% (38/50) respectively in the aprepitant group and the control group. There was no significant difference between the two groups (P=0.317). Within 24~120 hours, the CR rates of nausea were 36% (18/50) and 20% (10/50), respectively, and yet there was no significant difference between the two groups (P=0.075). Within 24 hours, the CR rates of vomiting were 94% (47/50) and 84% (42/50) respectively in aprepi-tant group and control group, showing no statistical difference between the two groups (P=0.110). However, the CR rate of vomiting within 24~120 hours was 84% (42/50) and 52% (26/50) respectively, with statistical difference between the two groups (P=0.001). The incidence of adverse reactions in the aprepitant group was similar to that of the control group. All of them wereⅠ-Ⅱ degree adverse reactions, which could be tolerated by the patients. Conclusion Aprepitant is effective and safe in the prevention of nausea and vomiting for patients with malignant tumors of bone and soft tissue during the course of high emetic chemotherapy within 24~120 hours.关键词
阿瑞匹坦/骨肿瘤/软组织肉瘤/化疗/恶心/呕吐Key words
Aprepitant/Bone neoplasms/Soft tissue sarcoma/Chemotherapy/Nausea/Vomiting分类
医药卫生引用本文复制引用
ZHANG Jiao,LIU Huayun,WANG Yuhua..阿瑞匹坦预防骨与软组织肿瘤患者接受高致吐化疗所致恶心、呕吐的研究[J].肿瘤药学,2019,9(2):270-274,5.
